Data from phase III trials of Taltz (ixekizumab) in plaque psoriasis published in JAMA Dermatology- Eli Lilly

Eli Lilly announced that JAMA Dermatology has published detailed results from three pivotal Phase III trials that evaluated the effect of Taltz (ixekizumab) on work productivity in patients with moderate-to-severe plaque psoriasis. In an analysis of the UNCOVER-1, UNCOVER-2 and UNCOVER-3 studies, the effect of ixekizumab on work productivity was evaluated by the change from baseline as measured by Work Productivity and Activity Impairment-Psoriasis (WPAI-PSO) scores at 12 weeks. The validated, self-reported WPAI questionnaire is used to measure impairment of work activities due to general health or a specific condition.

In all three studies, patients treated with ixekizumab reported improved work productivity compared to patients treated with placebo. In UNCOVER-1, improvements in work productivity were also sustained up to 60 weeks in those who demonstrated initial clinical response to ixekizumab at 12 weeks. Specific results from the UNCOVER-1 study were also presented during the American Academy of Dermatology (AAD) Annual Meeting in Washington, D.C.